Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Beckermann, K.; Campbell, M. T.; Haas, N. B.; Ornstein, M. C.; Gao, X.; Mao, S. S.; Hammers, H. J.; George, S.; Nelson, A. A.; Gourdin, T. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • (89) Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study
    Meeting Abstract

    Shuch, B. M.; Pantuck, A. J.; Bernhard, J. C.; Morris, M.; Master, V. A.; Scott, A. M.; Van Praet, C.; Bailly, C.; Onal, B.; Aksoy, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression
    Meeting Abstract

    Pal, S. K.; Twardowski, P.; Chen, D. L.; Hall, E. T.; Hays, D.; Wilson, I.; Schmiedehausen, K.; Ferris, M.; Le, W.; Postow, M. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial
    Meeting Abstract

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Barthélémy, P.; Goh, J. C.; Cutuli, H. J.; Simsek, B.; Spiridigliozzi, J.; Chudnovsky, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial
    Meeting Abstract

    Economides, M. P.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S. P.; Rosenberg, J. E.; Hochman, T.; Goldberg, J. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Lee, C. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent Duran, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial
    Meeting Abstract

    Cella, D.; Choueiri, T. K.; Blum, S. I.; Ejzykowicz, F.; Wallace, J.; Zhang, J.; Simsek, B.; Ivanescu, C.; Motzer, R. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J. R.; Goh, J. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save